Lessons from the controversy over statins
As the chair of the Committee on Publication Ethics (COPE), I would like to respond to the remarks of Richard Horton in his Offl ine Comment 1 (Sept 10, p 1040) about the role and actions of COPE, in which he highlighted the statins Review by Collins and colleagues. 2 COPE is an international inter disciplinary organisation, not just a UK one, whose remit is the provision of education and advice to members with questions about publication ethics. We do have a process whereby an individual can bring to our attention complaints about journal processes, but we cannot interfere in editorial decisions, or investigate the underlying issues of a complaint because we have neither the res ources nor-more importantly-the appropriate level of subject-specific expertise.
Horton states that "COPE declined to act further"; however, this is incorrect. COPE did request details of processes at the British Medical Journal (BMJ), in accordance with our remit. The guidance issued from COPE's review (I was not part of this having recused myself because of a potential confl ict of interest) off ered constructive criticism about how BMJ had managed the peer review process. 3 BMJ had already addressed those issues following their own independent review and COPE was satisfi ed with the procedural changes that were implemented.
Because it is not appropriate for COPE to make any specifi c judgment about effects on public health, COPE also recommended that Collins and colleagues engaged in open dialogue on the specifi c issues in the medical literature. We note this has now happened with the publication of their Review in The Lancet.
Putting the correction of Richard Horton's Comment to one side, and instead looking for useful lessons, COPE would be willing to discuss his suggestion for an independent tribunal. This tribunal would probably need public funding and the ability to apply sanctions and, to a degree, the ability to become a regulator for the research community. This is not COPE's remit, but we are interested in being part of the discussion on such an approach.
I am the Chair of COPE. At PLOS I worked previously with one of the BMJ staff who subsequently handled the complaint from Rory Collins and colleagues to the BMJ. I have co-authored a paper with Fiona Godlee, the BMJ Editor in Chief.
Virginia Barbour

cope_chair@publicationethics.org
Committee on Publication Ethics, Brisbane, QLD 4000, Australia 
Editor's reply
I'm grateful to Virginia Barbour for responding to the criticisms of the Committee on Publication Ethics (COPE). And I very much welcome her endorsement of the idea for an independent tribunal to consider allegations of research or publication malpractice. However, if she had quoted my words fully and fairly, I think she would have to agree that the claim that "COPE declined to act further" in response to "a direct request [to] conduct an independent investigation" 1 was correct. COPE did decline to act further, and this refusal has led to the current exchange. The questions raised by a group of respected scientists, together with
Authors' reply
Virginia Barbour states in her letter that, with respect to the submission to the Committee on Publication Ethics (COPE) in October, 2014, by a group of senior doctors and scientists, she had "recused myself because of a potential conflict of interest". However, that is not strictly accurate; Barbour only recused herself in September, 2015, 8 months after she had adjudicated on the submission in January, 2015.
In that adjudication, Barbour had not addressed any of the specifi c concerns that had been raised about failures of editorial integrity at the British Medical Journal (BMJ), and had not reviewed any of the supporting material that was provided as links within the submission, so she was asked in February, 2015, to address these issues specifi cally.
Barbour was then also responsible for sharing the submission with the BMJ several months before recusing herself. In June, 2015, a response from the BMJ was addressed in a second substantive submission from the group of senior doctors and scientists, which reiterated their concerns and again asked that COPE address each of them specifi cally.
It was only in September, 201 5, that Barbour stated that she was recusing herself because she had a potential confl ict of interest. The nature of that competing interest was not made clear (and it is not disclosed in her letter), but what is clear is that Barbour did not recuse herself before having determined the outcome of COPE's review. Indeed, conclusions from Barbour's report are being used as the basis for asserting that COPE has conducted a properly independent review of the issues raised. 1 After Barbour did recuse herself, it took until April, 2016, before COPE eventually stated that it felt the BMJ had taken steps to correct its mistakes. However, COPE still did not address any of the specific concerns raised about failures of editorial integrity at the BMJ or the adverse effect on public health of the misleading claims that the BMJ had published about side-eff ect rates with statins.
COPE was again asked to address these points specifi cally. However, it refused to do so and also refused to allow the matter to be considered by its Ombudsman, writing in July, 2016, that it regarded "this matter as closed as there is nothing further that we can usefully bring to this debate". Therefore, it is difficult to understand Barbour's other assertion that Richard Horton was incorrect in stating that COPE declined to act further. 2 In parallel with Barbour, the Editor of the BMJ has suggested in a Letter 3 that Horton's Offline Comment 2 was incorrect because he had not had access to the material submitted to COPE (including by the BMJ) and its responses. However, that is not correct: a detailed description of this sequence of events, along with links to the submissions to COPE and its responses, was made available at the Cholesterol Treatment Trialists' Collaboration website 4 in June, 2016, and other related material was also provided to The Lancet.
Our Lancet Review 5 provides a detailed explanation of the reasons why the available evidence from the randomised controlled trials provides a more reliable basis for assessing the safety and effi cacy of statin therapy than does observational evidence from case reports or health-care databases. Its intention is to help ensure that doctors and their patients are properly informed about the safety and effi cacy of statin therapy (and not, as stated by the BMJ's editor, 6 to shut down debate).
As Barbour's letter demonstrates, Horton's proposal for a tribunal that could address such matters of public health importance independently of the journals does need to be explored further. However, in the meantime, the failure of the BMJ to deal properly with the seriously misleading claims about the effects of statin therapy that it published, and then the failure of COPE to deal properly with editorial failures at the BMJ, is continuing to have an adverse impact on public health worldwide.
Along with several other scientists and doctors, we were cosignatories to the submission to COPE and coauthors of the recent Lancet Review of the safety and effi cacy of statin therapy. The CTSU has received grant funding from the pharmaceutical industry for independent research; our approach to maintaining the independence of that research is described at https://www.ctsu.ox.ac.uk/research/ctsuindependent-research_27june14.pdf and to maintaining our own independence by not taking honoraria or consultancy payments from industry is described at https://www.ctsu.ox.ac.uk/about/ctsu_ honoraria_25june14-1.pdf. Jane Armitage, Colin Baigent, *Rory Collins rory.collins@ndph.ox.ac.uk
